Works matching IS 2160763X AND DT 2024 AND VI 13 AND IP 9

Results: 13

Consideration of the Root Causes in Candidate Attrition During Oncology Drug Development.

Published in:

Clinical Pharmacology in Drug Development, 2024, v. 13, n. 9, p. 952, doi. 10.1002/cpdd.1464

By:

Kuo, Yin‐Ming;
Barrett, Jeffrey S.

Publication type:

Article

Population Pharmacokinetics of Naloxegol in Pediatric Subjects Receiving Opioids.

Published in:

Clinical Pharmacology in Drug Development, 2024, v. 13, n. 9, p. 974, doi. 10.1002/cpdd.1457

By:

Hruska, Matthew W.;
Mascelli, Mary Ann;
Liao, Sam;
Liao, Lori;
Davies, Patrick;
Kong, Jennifer;
Marsteller, Douglas A.

Publication type:

Article

The Bioequivalence of Abexinostat (CRA‐024781) Tosylate Tablets (20 mg) in Chinese Healthy Subjects Under Fasting Conditions.

Published in:

Clinical Pharmacology in Drug Development, 2024, v. 13, n. 9, p. 1061, doi. 10.1002/cpdd.1448

By:

Li, Xiang;
Guo, Wenqiang;
Chen, Jian;
Tan, Gewen

Publication type:

Article

Clinical Implications of Co‐administering Apixaban with Key Interacting Medications.

Published in:

Clinical Pharmacology in Drug Development, 2024, v. 13, n. 9, p. 961, doi. 10.1002/cpdd.1446

By:

Favatella, Nicholas;
Dalton, David;
Byon, Wonkyung;
Merali, Samira J.;
Klem, Christian

Publication type:

Article

Effect of Mild or Moderate Hepatic Impairment on the Pharmacokinetics of Avacopan, a Small‐Molecule Complement C5a Receptor Antagonist, for the Treatment of Antineutrophil Cytoplasmic Autoantibody‐Associated Vasculitis.

Published in:

Clinical Pharmacology in Drug Development, 2024, v. 13, n. 9, p. 1000, doi. 10.1002/cpdd.1444

By:

Miao, Shichang;
Suso, Pablo;
Furst, John A.;
Hudson, Matthew G.;
Trivedi, Ashit

Publication type:

Article

Food Effect and Pharmacokinetic Bridging of Avacopan in Caucasian and Japanese Healthy Participants.

Published in:

Clinical Pharmacology in Drug Development, 2024, v. 13, n. 9, p. 1011, doi. 10.1002/cpdd.1436

By:

Miao, Shichang;
Bekker, Pirow;
Armas, Danielle;
Lor, Mary;
Hanada, Ryuzo;
Okamura, Shota;
Umezawa, Yuko;
Trivedi, Ashit

Publication type:

Article

Comparative Bioequivalence Study of 2 Clopidogrel 75‐mg Tablet Formulations in Moroccan Volunteers.

Published in:

Clinical Pharmacology in Drug Development, 2024, v. 13, n. 9, p. 1044, doi. 10.1002/cpdd.1442

By:

Orche, Aimen El;
Khabbaz, Choukri El;
Cheikh, Amine;
Bouchafra, Houda;
Jawhari, Samira;
Abbes, Faouzi My El;
Cherrah, Yahya

Publication type:

Article

A Phase 1, Randomized, Double‐Blind, Placebo‐Controlled, Single Ascending Dose Trial of AWZ1066S, an Anti‐Wolbachia Candidate Macrofilaricide.

Published in:

Clinical Pharmacology in Drug Development, 2024, v. 13, n. 9, p. 1071, doi. 10.1002/cpdd.1441

By:

Devereux, Graham;
Bula, Marcin;
Tripp, Karen;
Fitzgerald, Richard;
Eraut, Nicola;
Alam, Muhammad Salman;
Moriyama, Tomoyuki;
Shinkyo, Raku;
Walker, Lauren;
Wang, Duolao;
Gusovsky, Fabian;
van der Velde, Jeannette;
Turner, Joseph D.;
Hong, Weiqian David;
O'Neill, Paul M.;
Taylor, Mark J.;
Ward, Stephen A.

Publication type:

Article

SERENE ER Analysis Part 1‐SERENE CD: Exposure‐Response Analysis of Higher Versus Standard Adalimumab Dosing Regimens for Patients With Moderately to Severely Active Crohn Disease.

Published in:

Clinical Pharmacology in Drug Development, 2024, v. 13, n. 9, p. 1024, doi. 10.1002/cpdd.1438

By:

Chen, Mong‐Jen;
Ponce‐Bobadilla, Ana Victoria;
Stodtmann, Sven;
Song, Alexandra P.;
Finney‐Hayward, Tricia K.;
Mostafa, Nael M.

Publication type:

Article

SERENE ER Analysis Part 2 SERENE‐UC: Exposure‐response Analysis of Higher Versus Standard Adalimumab Dosing Regimens for Patients with Moderately to Severely Active Ulcerative Colitis.

Published in:

Clinical Pharmacology in Drug Development, 2024, v. 13, n. 9, p. 1033, doi. 10.1002/cpdd.1437

By:

Stodtmann, Sven;
Chen, Mong‐Jen;
Ponce‐Bobadilla, Ana Victoria;
Finney‐Hayward, Tricia K.;
Kalabic, Jasmina;
Mostafa, Nael M.

Publication type:

Article

Safety and Pharmacokinetics of a Combined Antioxidant Therapy against Myocardial Reperfusion Injury: A Phase 1 Randomized Clinical Trial in Healthy Humans.

Published in:

Clinical Pharmacology in Drug Development, 2024, v. 13, n. 9, p. 1051, doi. 10.1002/cpdd.1443

By:

Gajardo Cortez, Abraham I.J.;
Lillo‐Moya, José;
San‐Martín‐Martinez, Daniel;
Pozo‐Martinez, Josue;
Morales, Pablo;
Prieto, Juan C.;
Aguayo, Rubén;
Puentes, Ángel;
Ramos, Cristobal;
Silva, Solange;
Catalán, Mabel;
Ramos, Karla;
Olea‐Azar, Claudio;
Rodrigo, Ramón

Publication type:

Article

Enhanced Bioavailability and Reduced Variability of Dasatinib and Sorafenib with a Novel Amorphous Solid Dispersion Technology Platform.

Published in:

Clinical Pharmacology in Drug Development, 2024, v. 13, n. 9, p. 985, doi. 10.1002/cpdd.1416

By:

Lennernäs, Hans;
Brisander, Magnus;
Liljebris, Charlotta;
Jesson, Gérald;
Andersson, Per

Publication type:

Article

Issue Information.

Published in:: Clinical Pharmacology in Drug Development, 2024, v. 13, n. 9, p. 947, doi. 10.1002/cpdd.1122
Publication type:: Article